Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 1460: Comparison of radiosensitizing effects of several PARP inhibitors under clinical investigation

View through CrossRef
Abstract Targeting tumor DNA repair is an attractive strategy in selectively killing tumors while sparing normal tissues. Inhibiting Poly (ADP-ribose) polymerase (PARP) in cancers with BRCA1 and BRCA2 mutations has been shown to be a promising approach either as a single agent or in combination therapy with chemotherapeutics or ionizing radiation. To systematically compare the radiosensitizing efficacy of various PARP inhibitors we have evaluated the long-term cytotoxicity of ABT-888, AZD2281, MK4827, and BSI-201 in clonogenic survival assays in combination with ionizing radiation. For these studies we used the breast cancer cell lines MDA-MB 231 BR, a subline of MDA-MB-231 selected for its tendency to metastasize to brain (BRCA1+/−) and MX-1 (BRCA1 deletion and BRCA2 mutation). Furthermore, we have evaluated PARP inhibitors under normoxic and hypoxic conditions (21% O2 versus 0.1% O2). In MDA-MB 231 BR cells, at a clinically relevant and achievable concentration for ABT-888 (J Clin Oncol. 2009; 27(16)) and AZD2281(N Engl J Med. 2009; 361(2)), and at 1 uM MK4827 showed radiosensitizing effects under both normoxic and hypoxic conditions. BSI-201 at a clinically achievable concentration (ASCO 2010, Abstract 2012) did not exhibit radiosensitizing effects under the same conditions. When MX-1 cells were treated with BSI-201 under hypoxic conditions (0.1% O2) the cytotoxicity of BSI-201 was evident. Taken together, the results show that ABT-888, AZD2281 and MK4827 show promising radiosensitizing effects under both normoxic and hypoxic conditions whereas the cytotoxicity of BSI-201 was observed only under hypoxic conditions in BRCA1/2 mutant carrier MX-1cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1460. doi:1538-7445.AM2012-1460
Title: Abstract 1460: Comparison of radiosensitizing effects of several PARP inhibitors under clinical investigation
Description:
Abstract Targeting tumor DNA repair is an attractive strategy in selectively killing tumors while sparing normal tissues.
Inhibiting Poly (ADP-ribose) polymerase (PARP) in cancers with BRCA1 and BRCA2 mutations has been shown to be a promising approach either as a single agent or in combination therapy with chemotherapeutics or ionizing radiation.
To systematically compare the radiosensitizing efficacy of various PARP inhibitors we have evaluated the long-term cytotoxicity of ABT-888, AZD2281, MK4827, and BSI-201 in clonogenic survival assays in combination with ionizing radiation.
For these studies we used the breast cancer cell lines MDA-MB 231 BR, a subline of MDA-MB-231 selected for its tendency to metastasize to brain (BRCA1+/−) and MX-1 (BRCA1 deletion and BRCA2 mutation).
Furthermore, we have evaluated PARP inhibitors under normoxic and hypoxic conditions (21% O2 versus 0.
1% O2).
In MDA-MB 231 BR cells, at a clinically relevant and achievable concentration for ABT-888 (J Clin Oncol.
2009; 27(16)) and AZD2281(N Engl J Med.
2009; 361(2)), and at 1 uM MK4827 showed radiosensitizing effects under both normoxic and hypoxic conditions.
BSI-201 at a clinically achievable concentration (ASCO 2010, Abstract 2012) did not exhibit radiosensitizing effects under the same conditions.
When MX-1 cells were treated with BSI-201 under hypoxic conditions (0.
1% O2) the cytotoxicity of BSI-201 was evident.
Taken together, the results show that ABT-888, AZD2281 and MK4827 show promising radiosensitizing effects under both normoxic and hypoxic conditions whereas the cytotoxicity of BSI-201 was observed only under hypoxic conditions in BRCA1/2 mutant carrier MX-1cells.
Citation Format: {Authors}.
{Abstract title} [abstract].
In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1460.
doi:1538-7445.
AM2012-1460.

Related Results

Abstract PR-10: PARP inhibition induces genomic instability in normal human cells.
Abstract PR-10: PARP inhibition induces genomic instability in normal human cells.
Abstract Recent research has focused on poly(ADP-ribose) polymerases (PARPs) as potential chemotherapeutic targets. Tumors which harbor defects in DNA double-strand ...
PARP inhibitors in melanoma treatment: potential, challenges, and future directions
PARP inhibitors in melanoma treatment: potential, challenges, and future directions
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombina...
PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to Achieve
PARP Inhibition as a Treatment Modality in Melanoma: What We Have Learned and What We Hope to Achieve
Genome integrity is a critical driver of cellular stability, and defects in the processes that maintain genome health are potent sources of cancer progression. Homologous recombina...
Abstract 1596: Evaluation of radiosensitizing effects of KSP inhibition in cancer cells.
Abstract 1596: Evaluation of radiosensitizing effects of KSP inhibition in cancer cells.
Abstract Background: Several chemotherapeutic agents act as radiosensitizers, priming the cancer cells to the effects of ionizing radiation and resulting in increase...
PARP Inhibitors As Anticancer Agents
PARP Inhibitors As Anticancer Agents
Abstract Poly(ADP‐ribosyl)ation is posttranslation covalent modification, which is operated by a family of enzymes whose founding member, named PARP‐1, has been involved ...
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy
Poly-(ADP-ribose) polymerase 1 (PARP1) is commonly known for its vital role in DNA damage response and repair. However, its enzymatic activity has been linked to a plethora of phys...
[RETRACTED] Keanu Reeves CBD Gummies v1
[RETRACTED] Keanu Reeves CBD Gummies v1
[RETRACTED]Keanu Reeves CBD Gummies ==❱❱ Huge Discounts:[HURRY UP ] Absolute Keanu Reeves CBD Gummies (Available)Order Online Only!! ❰❰= https://www.facebook.com/Keanu-Reeves-CBD-G...

Back to Top